199 related articles for article (PubMed ID: 16978037)
1. Extended-release intramuscular naltrexone.
Swainston Harrison T; Plosker GL; Keam SJ
Drugs; 2006; 66(13):1741-51. PubMed ID: 16978037
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.
Garbutt JC; Kranzler HR; O'Malley SS; Gastfriend DR; Pettinati HM; Silverman BL; Loewy JW; Ehrich EW;
JAMA; 2005 Apr; 293(13):1617-25. PubMed ID: 15811981
[TBL] [Abstract][Full Text] [Related]
3. Extended-release intramuscular naltrexone: a viewpoint by Falk Kiefer.
Kiefer F
Drugs; 2006; 66(13):1752-3. PubMed ID: 16978039
[No Abstract] [Full Text] [Related]
4. Extended-release intramuscular naltrexone: a viewpoint by Steven Siegel.
Siegel S
Drugs; 2006; 66(13):1752. PubMed ID: 16978040
[No Abstract] [Full Text] [Related]
5. Extended-release intramuscular naltrexone: a viewpoint by Henry R Kranzler.
Kranzler HR
Drugs; 2006; 66(13):1753-4. PubMed ID: 16978038
[No Abstract] [Full Text] [Related]
6. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment.
O'Malley SS; Garbutt JC; Gastfriend DR; Dong Q; Kranzler HR
J Clin Psychopharmacol; 2007 Oct; 27(5):507-12. PubMed ID: 17873686
[TBL] [Abstract][Full Text] [Related]
7. Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients.
Pettinati HM; Gastfriend DR; Dong Q; Kranzler HR; O'Malley SS
Alcohol Clin Exp Res; 2009 Feb; 33(2):350-6. PubMed ID: 19053979
[TBL] [Abstract][Full Text] [Related]
8. Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients.
Syed YY; Keating GM
CNS Drugs; 2013 Oct; 27(10):851-61. PubMed ID: 24018540
[TBL] [Abstract][Full Text] [Related]
9. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence.
Johnson BA; Ait-Daoud N; Aubin HJ; Van Den Brink W; Guzzetta R; Loewy J; Silverman B; Ehrich E
Alcohol Clin Exp Res; 2004 Sep; 28(9):1356-61. PubMed ID: 15365306
[TBL] [Abstract][Full Text] [Related]
10. A delayed injection-site reaction in a patient receiving extended-release naltrexone.
Ahamad K; Korthuis PT; Lum PJ; Johnson C; Wood E
Subst Abus; 2016; 37(2):278-80. PubMed ID: 26820699
[TBL] [Abstract][Full Text] [Related]
11. Vivitrex (Alkermes/Cephalon).
Heading CE
Curr Opin Investig Drugs; 2006 Jan; 7(1):81-8. PubMed ID: 16425675
[TBL] [Abstract][Full Text] [Related]
12. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
[TBL] [Abstract][Full Text] [Related]
13. Early treatment response in alcohol dependence with extended-release naltrexone.
Ciraulo DA; Dong Q; Silverman BL; Gastfriend DR; Pettinati HM
J Clin Psychiatry; 2008 Feb; 69(2):190-5. PubMed ID: 18348601
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.
Pettinati HM; Silverman BL; Battisti JJ; Forman R; Schweizer E; Gastfriend DR
Alcohol Clin Exp Res; 2011 Oct; 35(10):1804-11. PubMed ID: 21575016
[TBL] [Abstract][Full Text] [Related]
15. Long-acting injectable naltrexone for the treatment of alcohol dependence.
Mannelli P; Peindl K; Masand PS; Patkar AA
Expert Rev Neurother; 2007 Oct; 7(10):1265-77. PubMed ID: 17939765
[TBL] [Abstract][Full Text] [Related]
16. A synopsis of the pharmacological rationale, properties and therapeutic effects of depot preparations of naltrexone for treating alcohol dependence.
Johnson BA
Expert Opin Pharmacother; 2006 Jun; 7(8):1065-73. PubMed ID: 16722816
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial.
Galloway GP; Koch M; Cello R; Smith DE
BMC Psychiatry; 2005 Apr; 5():18. PubMed ID: 15804355
[TBL] [Abstract][Full Text] [Related]
18. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.
Dunbar JL; Turncliff RZ; Dong Q; Silverman BL; Ehrich EW; Lasseter KC
Alcohol Clin Exp Res; 2006 Mar; 30(3):480-90. PubMed ID: 16499489
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial.
Edelman EJ; Moore BA; Holt SR; Hansen N; Kyriakides TC; Virata M; Brown ST; Justice AC; Bryant KJ; Fiellin DA; Fiellin LE
AIDS Behav; 2019 Jan; 23(1):211-221. PubMed ID: 30073637
[TBL] [Abstract][Full Text] [Related]
20. Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics.
Lucey MR; Silverman BL; Illeperuma A; O'Brien CP
Alcohol Clin Exp Res; 2008 Mar; 32(3):498-504. PubMed ID: 18241321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
